Conference proceedings from the 23rd Bangkok International Symposium on HIV Medicine
- 1 April 2021
- journal article
- research article
- Published by Future Medicine Ltd in Future Virology
- Vol. 16 (4), 255-276
- https://doi.org/10.2217/fvl-2021-0029
Abstract
The Bangkok International Symposium on HIV Medicine is the longest running HIV conference in the Asia-Pacific, that provides professional healthcare workers with the latest information on HIV and related fields. For the first time, this event was held as a virtual symposium due to the COVID-19 pandemic and registration was free to everyone. More than 1800 people viewed the symposium from 41 countries. The first sessions reviewed COVID-19 and had a panel representing physicians from Australia, Myanmar, Indonesia and Thailand, who shared experiences in managing HIV care during the pandemic. For the first time, we had sessions on the WHO’s vision for integrating HIV care delivery models, and a number of physicians shared the innovative models that have been developed in their clinics.Keywords
Funding Information
- Atlanta
- CAMBER
- Cepheid
- Gilead Sciences
- GSK ViiV
- Oxford Immunotec
- Sysmex Corporation
- Thailand Convention and Exhibition Bureau
- The Government Pharmaceutical Organization
- TREAT Asia
- VIATRIS | Mylan + Upjohn
- ViiV Healthcare
This publication has 13 references indexed in Scilit:
- Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal DisordersAntimicrobial Agents and Chemotherapy, 2020
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialThe Lancet, 2020
- Clinical targeting of HIV capsid protein with a long-acting small moleculeNature, 2020
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialThe Lancet HIV, 2020
- Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settingsAIDS, 2020
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialThe Lancet HIV, 2020
- Final Analysis of a Trial of M72/AS01E Vaccine to Prevent TuberculosisThe New England Journal of Medicine, 2019
- Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender menJournal of the International AIDS Society, 2019
- Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationThe New England Journal of Medicine, 2018
- Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette–Guérin vaccination against tuberculosisHealth Technology Assessment, 2013